HDAC9 and cancer: This research emphasizes that only five HDAC inhibitors—vorinostat, belinostat, panobinostat, pracinostat, and romidepsin—have principally demonstrated therapeutic benefits in hematological malignancies and have been licensed by the FDA for cancer treatment.